HIF Enhancer與Erythropoietin的比較

Comparison of HIF Enhancer and Erythropoietin

江哲甫(Che-Fu Chiang) ； 王德群(Te-Chun Wang) ； 巫宏傑(Hung-Chieh Wu) ； 王偉傑(Wei-Jie Wang) ； 丁瑞聰(Jui-Tsung Ting)

《腎臟與透析》 35卷1期 (2023/03) Pp. 45-47

https://doi.org/10.6340/KD.202303_35(1).0008

摘要

缺氧誘導因子脯氨醯羥化酶抑制劑（hypoxia-inducible factor prolyl hydroxylase inhibitors, HIF-PHIs）可刺激紅血球生成並調節鐵代謝。在第二期及第三期臨床試驗中，口服HIF-PHIs在慢性腎臟病（chronic kidney disease, CKD）患者及透析患者的貧血治療中，顯現不亞於epoetin alfa的效果。口服HIF-PHIs相較傳統的epoetin alfa注射提升較多的血色素、血中鐵離子濃度更為穩定、鐵調素（hepcidin）濃度下降較多，且藥物安全性方面兩者不相上下。綜合以上結論，口服HIF-PHIs有望成為除了紅血球生成刺激劑注射之外治療貧血的選擇。

關鍵字

缺氧誘導因子脯氨醯羥化酶抑制劑 ； 紅血球生成素 ； 貧血

並列摘要

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) stimulates erythropoiesis and regulates iron metabolism. In phase 2 and phase 3 trials, oral HIF-PHIs was noninferior to parenteral epoetin alfa as therapy for anemia. Comparing to epoetin alfa group, oral HIF-PHIs group has numerically greater mean (± standard deviation) change in hemoglobin level from baseline, and mean serum iron level was clinically stable, with an increase in the transferrin level and total iron-binding capacity. It has also shown comparative safety to epoetin alfa. As a result, oral HIF-PHIs may be an alternative to ESAs (erythropoiesis stimulating agents) injections for treating anemia among chronic kidney disease and patients receiving dialysis.

並列關鍵字

hypoxia-inducible factor prolyl hydroxylase inhibitors ； erythropoietin ； anemia